|  | | | RMST at times (years) | | | | Survival proportions at times (years) | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Treatment | Outcome | Source | 4 | 8 | 15 | 50\* | 4 | 8 | 15 | 50\* |
| **FC** | **OS** | **Observed** | **3.53** | **5.87** |  |  | **0.76** | **0.39** |  |  |
|  |  | SPMs, ASF (Williams et al.) | 3.53 | 5.61 | 6.87 | 7.08 | 0.73 | 0.34 | 0.08 | 0.00 |
|  |  | FPMs, ASF | 3.51 | 5.86 | 8.16 | 11.66 | 0.72 | 0.45 | 0.25 | 0.04 |
|  |  | FPMs, RSF (Proposed method) | 3.52 | 5.86 | 8.08 | 10.06 | 0.72 | 0.45 | 0.23 | 0.00 |
|  | **PFS** | **Observed** | **2.63** | **3.52** |  |  | **0.35** | **0.10** |  |  |
|  |  | SPMs, ASF | 2.55 | 2.74 | 2.74 | 2.74 | 0.22 | 0.00 | 0.00 | 0.00 |
|  |  | FPMs, ASF | 2.56 | 3.00 | 3.03 | 3.03 | 0.28 | 0.02 | 0.00 | 0.00 |
|  |  | FPMs, RSF | 2.56 | 3.00 | 3.02 | 3.02 | 0.28 | 0.02 | 0.00 | 0.00 |
|  | **PPS** | **Observed** | **0.90** | **2.35** |  |  | **0.41** | **0.41** |  |  |
|  |  | SPMs, ASF | 0.99 | 2.87 | 4.12 | 4.33 | 0.51 | 0.34 | 0.08 | 0.00 |
|  |  | FPMs, ASF | 0.95 | 2.86 | 5.14 | 8.64 | 0.45 | 0.43 | 0.25 | 0.04 |
|  |  | FPMs, RSF | 0.96 | 2.86 | 5.06 | 7.04 | 0.45 | 0.43 | 0.23 | 0.00 |
| **RFC** | **OS** | **Observed** | **3.66** | **6.44** |  |  | **0.83** | **0.55** |  |  |
|  |  | SPMs, ASF | 3.63 | 5.80 | 6.85 | 6.97 | 0.77 | 0.33 | 0.05 | 0.00 |
|  |  | FPMs, ASF | 3.62 | 6.12 | 8.24 | 10.39 | 0.77 | 0.47 | 0.20 | 0.01 |
|  |  | FPMs, RSF | 3.62 | 6.12 | 8.17 | 9.55 | 0.77 | 0.46 | 0.18 | 0.00 |
|  | **PFS** | **Observed** | **3.15** | **4.72** |  |  | **0.57** | **0.27** |  |  |
|  |  | SPMs, ASF | 3.01 | 3.52 | 3.52 | 3.52 | 0.42 | 0.00 | 0.00 | 0.00 |
|  |  | FPMs, ASF | 3.02 | 4.05 | 4.25 | 4.26 | 0.47 | 0.11 | 0.00 | 0.00 |
|  |  | FPMs, RSF | 3.02 | 4.06 | 4.25 | 4.26 | 0.47 | 0.11 | 0.00 | 0.00 |
|  | **PPS** | **Observed** | **0.51** | **1.72** |  |  | **0.26** | **0.26** |  |  |
|  |  | SPMs, ASF | 0.62 | 2.28 | 3.33 | 3.45 | 0.35 | 0.33 | 0.05 | 0.00 |
|  |  | FPMs, ASF | 0.60 | 2.06 | 3.99 | 6.13 | 0.30 | 0.36 | 0.19 | 0.01 |
|  |  | FPMs, RSF | 0.60 | 2.06 | 3.92 | 5.29 | 0.30 | 0.36 | 0.18 | 0.00 |
| \*If survival proportion at 50 years is zero, the reported 50-year RMST can be regarded as life expectancy. RMST, restricted mean survival time; LE, life expectancy; FC, fludarabine and cyclophosphamide; RFC, rituximab, fludarabine, and cyclophosphamide; SPMs, standard parametric models; FPMs, flexible parametric models; ASF, all-cause survival framework; RSF, relative survival framework; OS, overall survival; PFS, progression-free survival; PPS, post-progression survival. | | | | | | | | | | |